drugset / Trial / NCT04591717
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
Timeline
- Start
- 2020-10-19
- Primary completion
- 2022-04-20
- Completion
- 2023-01-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | hAd5-S-Fusion+N-ETSD | Vaccine | 0.5 ml | Subcutaneous |
| Subject | hAd5-S-Fusion+N-ETSD | Vaccine | 1 ml | Subcutaneous |
| Subject | hAd5-S-Fusion+N-ETSD | Vaccine | 5e+10 unknown | Subcutaneous |
| Subject | hAd5-S-Fusion+N-ETSD | Vaccine | 1e+11 unknown | Subcutaneous |